Lipicard's Platrol(R) - First Safe, Sustained Release Antiplatelet Drug Developed Through a Novel Platform Technology.HYDERABAD, India -- Platrol[R] has demonstrated 40% more efficacy and negligible toxicity resulting in higher therapeutic index compared to Aspirin, Clopidogrel and other anti-platelet drugs in clinical trials. Surprisingly, its inherent sustained release property makes Platrol[R] even better as a long-term cardio-protective drug. Pioneering studies by Garret Fitzgerald at the University of Pennsylvania (body, education) University of Pennsylvania - The home of ENIAC and Machiavelli. http://upenn.edu/. Address: Philadelphia, PA, USA. and other scientists in the 80's have shown that a controlled release formulation of Aspirin at the correct release rate will result in sustained specific irreversible acetylation acetylation /acet·y·la·tion/ (ah-set?i-la´shun) introduction of an acetyl radical into an organic molecule. a·cet·y·la·tion n. of platelets as they pass through the portal circulation portal circulation n. Circulation of blood to the liver from the small intestine via the portal vein. . This will enhance action of Aspirin in endothelium endothelium /en·do·the·li·um/ (-the´le-um) pl. endothe´lia the layer of epithelial cells that lines the cavities of the heart, the serous cavities, and the lumina of the blood and lymph vessels. , but mitigating its anti-Aspirin like activity if released into the systemic circulation. Recent human pharmacokinetic studies have shown that Platrol[R] behaves like a sustained release formulation. Also, the absence of known active metabolite in the systemic circulation in humans explains both its higher efficacy in portal circulation and lower systemic toxicity. Platrol[R], we believe acts similar to Aspirin - decreasing the blood clotting by dual mechanism - by inhibiting the Thromboxane thromboxane /throm·box·ane/ (-bok´san) either of two compounds, one designated A2 and the other B2. Thromboxane A2 is synthesized by platelets and is an inducer of platelet aggregation and platelet release functions and is a A2 synthesis and through chemical acetylation of the blood platelets. However, unlike Aspirin, Platrol[R] does not have the acidic group intact. Several GI irritation studies in a sensitive rat model showed Platrol[R] is devoid of this toxicity, while Aspirin caused acute severe hemorrhage and ulcers in the stomach. As reported earlier, Platrol[R] is far superior to all other drugs in the research pipeline including the Nitric Oxide (NO) donating derivatives of Aspirin. Lipicard's survey also revealed that US cardiologists are ready to prescribe Platrol[R] as and when it is available due to its higher efficacy and lower toxicity than Aspirin. Lipicard will share the details and profile of other safe drugs developed using a novel platform technology "Athena" soon. About Lipicard Technologies: Lipicard Technologies Limited develops innovative and novel High Therapeutic Index Drugs for Lipid management and cardio protection in collaboration with Life Enhancing Technologies LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control . USA. Platrol[R] is the first safe antiplatelet drug being developed for cardio-protection. Next in line are the integrated Lipid management drug for increasing HDL (Hardware Description Language) A language used to describe the functions of an electronic circuit for documentation, simulation or logic synthesis (or all three). Although many proprietary HDLs have been developed, Verilog and VHDL are the major standards. and lowering LDL LDL - ["LDL: A Logic-Based Data-Language", S. Tsur et al, Proc VLDB 1986, Kyoto Japan, Aug 1986, pp.33-41]. , and safe NSAIDs. Platrol[R] is registered trademarks of Life Enhancing Technologies. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion